A Brinkman

Summary

Affiliation: University Hospital Rotterdam
Country: The Netherlands

Publications

  1. ncbi BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells
    A Brinkman
    Department of Pathology Division of Molecular Biology, Josephine Nefkens Institute, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 92:112-20. 2000
  2. ncbi Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment
    S van der Flier
    Department of Pathology Division of Molecular Biology, Josephine Nefkens Institute, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 92:120-7. 2000
  3. ncbi Tamoxifen resistance in breast cancer: elucidating mechanisms
    L C Dorssers
    Department of Pathology, Josephine Nefkens Institute, University Hospital Rotterdam, The Netherlands
    Drugs 61:1721-33. 2001
  4. ncbi Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue
    S van der Flier
    Department of Pathology, Josephine Nefkens Institute, University Hospital Rotterdam Daniel den Hoed Cancer Center, The Netherlands
    Int J Biol Markers 16:172-8. 2001
  5. pmc Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)
    A Brinkman
    Department of Pediatrics, Erasmus University Sophia Childrens Hospital, Rotterdam, The Netherlands
    EMBO J 7:2417-23. 1988

Collaborators

Detail Information

Publications5

  1. ncbi BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells
    A Brinkman
    Department of Pathology Division of Molecular Biology, Josephine Nefkens Institute, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 92:112-20. 2000
    ..In this study, we isolated and characterized the crucial gene at the breast cancer antiestrogen resistance 1 (BCAR1) locus...
  2. ncbi Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment
    S van der Flier
    Department of Pathology Division of Molecular Biology, Josephine Nefkens Institute, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 92:120-7. 2000
    ..To investigate its role in clinical breast cancer, we determined the levels of Bcar1/p130Cas protein in a large series of primary breast carcinomas...
  3. ncbi Tamoxifen resistance in breast cancer: elucidating mechanisms
    L C Dorssers
    Department of Pathology, Josephine Nefkens Institute, University Hospital Rotterdam, The Netherlands
    Drugs 61:1721-33. 2001
    ....
  4. ncbi Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue
    S van der Flier
    Department of Pathology, Josephine Nefkens Institute, University Hospital Rotterdam Daniel den Hoed Cancer Center, The Netherlands
    Int J Biol Markers 16:172-8. 2001
    ..This immunohistochemical study demonstrates a variable expression of BCAR1/p130Cas in malignant and non-malignant breast epithelial cells, which may be of benefit for diagnostic purposes...
  5. pmc Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)
    A Brinkman
    Department of Pediatrics, Erasmus University Sophia Childrens Hospital, Rotterdam, The Netherlands
    EMBO J 7:2417-23. 1988
    ..The IBP-1 gene is a single copy gene, located on chromosome 7. The results obtained suggest that most, if not all, lower mol. wt IGF-binding proteins originate from this gene...